This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.
—I studied a series of 75 patients with a positive titer of Epstein-Barr virus (EBV) in my clinical neurology practice. The serologic findings were all greater than 1:80 for antibody to the anticapsular antigen.The patients were divided into three groups: (1) those with bilateral sciatic neuropathy, a monophasic illness, with follow-up to two years; (2) those with clinical multiple sclerosis but normal CSF, including the absence of oligoclonal antibody; and (3) those with clinical multiple sclerosis with abnormal CSF, including the presence of oligoclonal antibody.The usual clinical laboratory test for mononucleosis was negative weeks to months after clinical onset. The assay for antibody to anticapsular antigen was positive for extended periods after infection or exposure. The virus was a DNA virus. With the current use of antiviral agents to include effective treatments for herpes encephalitis, it was thought that this association was important. The quantitative
Richardson JR. Demyelinating Disease: Association With Epstein-Barr Virus. Arch Neurol. 1984;41(1):14–15. doi:10.1001/archneur.1984.04050130016007
Neurology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.